Molecular therapy for Myocardial Infarction: Galectin-7 improves myocardial function after myocardial infarction via up-regulation of PNUTS, 16/November/2016, 7.13 pm

MiRNA-based therapy for Breast Cancer: Inhibitor Of Growth Family Member 1 (p33ING1b) increases the level of tumor suppressor p53, inhibits the proliferation of tumor-initiating cells in breast cancer, suppresses the progression of metastatic breast cancer, and supports tumor relapse-free survival in breast cancer patients, 16/November/2015, 6.36 pm
November 16, 2016
Natural product Lifespan extension therapy: Methyl 3,5-dicaffeoyl quinate (MDQ), found in Kalopanax pictus, Salicornia herbacea L., Aster oharai and Solidago virga-aurea var. gigantean, increases life span via up-regulation of its target gene BubR1, 11/November/2016, 10.04 am
November 16, 2016
Show all

Introduction: What they say

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.

What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-price-100cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction: Galectin-7 improves myocardial function after myocardial infarction via  up-regulation of PNUTS


Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.

From Research Findings to Therapeutic Opportunity

This study suggests small molecule-based cardiac regeneration therapy. Galectin-7, by decreasing the expression of its target gene, it may increase the expression of PNUTS. Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardiomyocyte survival/regeneration.

Thus, by treating cardiac patients with Galectin-7 activators, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that Galectin-7 activators can be used to improve myocardial function and prevent myocardial infarction. 

Details of the Research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Undisclosed Mechanistic insights: How  does  Galectin-7 increase the expression of PNUTS?

Terms & Conditions apply

Amount: $300#

# Research cooperation


Web: or

CitationBoominathan, L.,  Molecular therapy for Myocardial Infarction: Galectin-7  improves myocardial function after myocardial infarction via  up-regulation of PNUTS, 16/November/2016, 7.13 pm,  Genome-2-Bio-Medicine Discovery center (GBMD),

Courtesy: When you cite drop us a line at

Comments are closed.